MX368459B - Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. - Google Patents

Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Info

Publication number
MX368459B
MX368459B MX2016000153A MX2016000153A MX368459B MX 368459 B MX368459 B MX 368459B MX 2016000153 A MX2016000153 A MX 2016000153A MX 2016000153 A MX2016000153 A MX 2016000153A MX 368459 B MX368459 B MX 368459B
Authority
MX
Mexico
Prior art keywords
preventing
nervous system
central nervous
degenerative disorders
novel compositions
Prior art date
Application number
MX2016000153A
Other languages
English (en)
Inventor
Boyd Robert
Lee Gary
Rybczynski Philip
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX368459B publication Critical patent/MX368459B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, así como también composiciones y métodos que los usan para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. En particular, la presente invención proporciona métodos para prevenir y/o tratar la enfermedad de Parkinson.
MX2016000153A 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. MX368459B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25280309P 2009-10-19 2009-10-19

Publications (1)

Publication Number Publication Date
MX368459B true MX368459B (es) 2019-10-03

Family

ID=43879775

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000153A MX368459B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2012004548A MX340807B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012004548A MX340807B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Country Status (26)

Country Link
US (4) US8604206B2 (es)
EP (2) EP3143875B1 (es)
JP (2) JP5805649B2 (es)
KR (3) KR101880411B1 (es)
CN (2) CN105367485B (es)
AR (1) AR078606A1 (es)
AU (3) AU2010308396B2 (es)
BR (1) BR112012009121A2 (es)
CA (1) CA2778348C (es)
CY (1) CY1118966T1 (es)
DK (1) DK2490532T3 (es)
ES (2) ES2617192T3 (es)
HR (1) HRP20170236T1 (es)
HU (1) HUE033116T2 (es)
IL (1) IL219160B (es)
LT (1) LT2490532T (es)
MX (2) MX368459B (es)
PL (1) PL2490532T3 (es)
PT (1) PT2490532T (es)
RS (1) RS55679B1 (es)
RU (2) RU2015147509A (es)
SG (1) SG10201507159XA (es)
SI (1) SI2490532T1 (es)
SM (2) SMT201700105T1 (es)
TW (1) TWI642434B (es)
WO (1) WO2011049736A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608520C2 (ru) 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
KR101880411B1 (ko) 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
EP2591823A1 (en) * 2011-11-11 2013-05-15 Biologische Heilmittel Heel GmbH Composition for treating or preventing neurodegenerative disorders
US9464050B2 (en) 2012-03-27 2016-10-11 Amicus Therapeutics, Inc. Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
WO2015095963A1 (en) * 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
EP3615509A1 (en) 2017-04-25 2020-03-04 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
RU2676956C1 (ru) * 2017-08-25 2019-01-11 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko) 2018-01-19 2019-06-21 전남대학교산학협력단 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020223310A2 (en) * 2019-04-29 2020-11-05 Thomas Jefferson University Methods for treating neurodegenerative disorders
WO2022232360A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
EP4658726A1 (en) * 2023-01-31 2025-12-10 Bioeutectics Corporation Use of additives (adjuvants, anti freezing agents, antimicrobial and antioxidants) in natural deep eutectic solvents and mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
HK1001832A1 (en) 1991-04-25 1998-07-10 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
EP0749423B1 (en) * 1994-03-09 2003-06-18 Novo Nordisk A/S Piperidines and pyrrolidines
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー／エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
US20040082641A1 (en) * 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
AU2004308966A1 (en) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
DK1860101T3 (da) * 2006-05-24 2011-07-25 Amicus Therapeutics Inc Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
JP5303458B2 (ja) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
ES2505243T3 (es) * 2009-04-09 2014-10-09 Amicus Therapeutics, Inc. Agentes terapéuticos para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
CN102625661B (zh) 2009-04-09 2015-05-27 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的方法
US9044437B2 (en) * 2009-10-19 2015-06-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
RU2608520C2 (ru) * 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
KR101880411B1 (ko) 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
CA2778348C (en) 2022-08-23
JP2015157822A (ja) 2015-09-03
TW201116279A (en) 2011-05-16
CA2778348A1 (en) 2011-04-28
AR078606A1 (es) 2011-11-23
HRP20170236T1 (hr) 2017-04-07
KR20170096220A (ko) 2017-08-23
AU2010308396A1 (en) 2012-05-03
HK1219724A1 (zh) 2017-04-13
US8604206B2 (en) 2013-12-10
SMT201700105T1 (it) 2017-03-08
PT2490532T (pt) 2017-02-23
AU2016203817A1 (en) 2016-06-30
LT2490532T (lt) 2017-03-27
US20110092541A1 (en) 2011-04-21
TWI642434B (zh) 2018-12-01
AU2017272296A1 (en) 2018-01-25
RU2012120759A (ru) 2013-11-27
AU2010308396B2 (en) 2016-04-28
EP2490532B1 (en) 2016-11-23
MX2012004548A (es) 2012-07-04
AU2016203817B2 (en) 2017-09-07
ES2814178T3 (es) 2021-03-26
EP3143875B1 (en) 2020-05-27
KR20120104549A (ko) 2012-09-21
RU2015147509A (ru) 2019-01-14
EP3143875A1 (en) 2017-03-22
RS55679B1 (sr) 2017-07-31
KR101880411B1 (ko) 2018-07-19
JP2013508366A (ja) 2013-03-07
SG10201507159XA (en) 2015-10-29
AU2017272296B2 (en) 2019-07-11
PL2490532T3 (pl) 2017-05-31
EP2490532A1 (en) 2012-08-29
ES2617192T3 (es) 2017-06-15
SMT201700105B (it) 2017-03-08
HUE033116T2 (en) 2017-11-28
US20160326114A1 (en) 2016-11-10
JP5805649B2 (ja) 2015-11-04
IL219160B (en) 2018-12-31
EP2490532A4 (en) 2013-06-12
IL219160A0 (en) 2012-06-28
RU2581058C2 (ru) 2016-04-10
CN102655747A (zh) 2012-09-05
KR101813988B1 (ko) 2018-01-02
SI2490532T1 (sl) 2017-03-31
US10421724B2 (en) 2019-09-24
BR112012009121A2 (pt) 2017-08-29
CN105367485A (zh) 2016-03-02
WO2011049736A1 (en) 2011-04-28
KR101769396B1 (ko) 2017-08-18
JP6258245B2 (ja) 2018-01-10
US9409862B2 (en) 2016-08-09
KR20180001588A (ko) 2018-01-04
MX340807B (es) 2016-07-27
US20180273474A1 (en) 2018-09-27
DK2490532T3 (en) 2017-02-27
CN105367485B (zh) 2018-04-17
US20140080871A1 (en) 2014-03-20
CY1118966T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
SG179120A1 (en) Novel compounds
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY161415A (en) A homeopathic formulation
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2010007392A (es) Antagonistas de trpa1.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010007391A (es) Antagonistas de trpa1.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
TW200642690A (en) Composition for treating central nervous system disorders
WO2009151618A3 (en) Methods and compositions for treating alzheimer's disease